CancerEnD: A database of cancer associated enhancers

CancerEnD is an integrated resource developed for annotating 8524 unique expressed enhancers, associated genes, somatic mutations and copy number variations of 8063 cancer samples from 18 cancer types of TCGA. Somatic mutation data was taken from the COSMIC repository. To delineate the relationship...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Genomics (San Diego, Calif.) Calif.), 2020-09, Vol.112 (5), p.3696-3702
Hauptverfasser: Kumar, Rajesh, Lathwal, Anjali, Kumar, Vinod, Patiyal, Sumeet, Raghav, Pawan Kumar, Raghava, Gajendra P.S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:CancerEnD is an integrated resource developed for annotating 8524 unique expressed enhancers, associated genes, somatic mutations and copy number variations of 8063 cancer samples from 18 cancer types of TCGA. Somatic mutation data was taken from the COSMIC repository. To delineate the relationship of change in copy number of enhancer elements with the prognosis of cancer patients, survival analysis was done using the survival package in R. We identified 1762 overall survival associated enhancers, which can be used for prognostic purposes of cancer patients in a tissue-specific manner. CancerEnD (https://webs.iiitd.edu.in/raghava/cancerend/) is developed on a user-friendly responsive template, that enables searching, browsing and downloading of the annotated enhancer elements in terms of gene expression, copy number variation and survival association. We hope it provides a promising avenue for researchers to facilitate the understanding of enhancer deregulation in tumorigenesis, and to identify new biomarkers for therapy and disease-diagnosis. •CancerEnD stores information on cancer-associated enhancers, their genes, CNV and association with patient survival.•This study identifies enhancer-based tissue-specific prognostic biomarkers for 18 cancer types.•Overlapping and unique enhancers across cancer type explain heterogeneity among the different cancer types.
ISSN:0888-7543
1089-8646
DOI:10.1016/j.ygeno.2020.04.028